Green production method and device of levetiracetam key intermediate S-2-methyl aminobutyrate

Abstract

The invention discloses a green production method of a levetiracetam key intermediate S-2-methyl aminobutyrate, and belongs to the field of medicine preparation, the method comprises the following steps: S1, pumping a mixture of S-2-aminobutyric acid, methanol and thionyl chloride into a reaction kettle, heating and stirring for reaction, and extracting the hydrogen chloride and the sulfur dioxidegenerated by reaction from the top of the reaction kettle; s2, pumping the hydrogen chloride and the sulfur dioxide extracted from the top of the reaction kettle into the bottom of an absorption tower, and pumping an alkaline aqueous solution into the tower top to absorb the hydrogen chloride and sulfur dioxide gas; and S3, discharging the reaction liquid from the bottom of the reaction kettle, and carrying out atmospheric distillation to obtain the S-2-methyl aminobutyrate. According to the process method provided by the invention, the hydrogen chloride and the sulfur dioxide generated in the production process of the S-2- methyl aminobutyrate are effectively absorbed, so that the process is greener and more environment-friendly, and meanwhile, the conversion rate of the S-2-methyl aminobutyrate in the obtained reaction product is greater than 88%.

Description

technical field [0001] The invention relates to the field of medicine preparation, in particular to a key intermediate of levetiracetam S - Green production method and device for methyl 2-aminobutyrate. Background technique [0002] Levetiracetam is a pyrrolidone compound with the trade name Keppra. It applied for a preparation method patent in China in 1985, and was approved to be marketed in Europe in 1999. In April 2000, it was approved by FDA to be marketed in the United States. In March 2007, it was listed in China. Later, it was found in preclinical pharmacological experiments that it has a unique Antiepileptic effect. In addition to being used as adjuvant therapy for intractable epilepsy, its indications have also been gradually extended to monotherapy for newly diagnosed epilepsy, which has broad application prospects. Currently the only antiepileptic drug with unique properties to prevent epilepsy. In recent years, the production process of levetiracetam has alw...

AI Technical Summary

Problems solved by technology

But the disadvantage of this method is also more significant, that is, a large amount of hydrogen chloride and sulfur dioxide gas will be produced in the reaction process, and the discharge of this gas has caused serious pollution to the environment.

Images